Key result
Tirofiban combined with dual antiplatelet therapy significantly reduced NIHSS scores at 90 days (MD -0.82) compared to dual antiplatelet therapy alone in patients with acute ischemic stroke.
Why the study?
The study was conducted to evaluate the safety and efficacy of tirofiban in the treatment of acute ischemic stroke.
Does tirofiban combined with dual antiplatelet therapy improve neurological deficits and functional outcomes in acute ischemic stroke patients beyond the standard time window?
Population
152 AIS patients with small vessel occlusion without thrombolysis or endovascular treatment within 72 h of onset
Comparison
Dual antiplatelet therapy plus tirofiban vs dual antiplatelet therapy alone
Design
Retrospective study
Follow-up
90 days
Authors
Loading...
Tirofiban addition may be considered in small vessel AIS without reperfusion; hypothesis-generating and should not yet change practice.
Cohort (n=152)
No
Does tirofiban combined with dual antiplatelet therapy improve neurological deficits and functional outcomes in acute ischemic stroke patients beyond the standard time window?
Mean Difference: -0.82 (95% CI -1.29–-0.34)
p-value: p=<0.001
Tirofiban combined with dual antiplatelet therapy significantly improves neurological deficits and functional outcomes in acute ischemic stroke patients beyond the standard time window without increasing bleeding or mortality risks.
Yang et al. (2025) conducted a cohort in Acute ischemic stroke (n=152). Tirofiban vs. Dual antiplatelet therapy (aspirin + clopidogrel) was evaluated on NIHSS score at day 90 (MD -0.82, 95% CI -1.29, -0.34, p=<0.001). Tirofiban combined with dual antiplatelet therapy significantly reduced NIHSS scores at 90 days (MD -0.82) compared to dual antiplatelet therapy alone in patients with acute ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: